Global Market Expansion Zelira Therapeutics is actively expanding its presence in key markets such as the US, Australia, and Germany, presenting opportunities to offer localized cannabis research, compliance solutions, and distribution partnerships.

Innovative Drug Development With recent success in clinical trials for proprietary drug ZLT-L-007 targeting diabetic nerve pain, Zelira is positioned to attract collaborations and supply opportunities with healthcare providers seeking effective cannabinoid-based treatments.

Research and Partnerships Zelira’s strategic collaborations with contract research organizations like Affinity Bio Partners indicate ongoing investment in clinical development, opening avenues for CRO services, research funding, and joint ventures.

Financial Support Recent government funding and R&D tax incentives enhance Zelira’s financial capacity, making it receptive to investment opportunities, licensing deals, and co-development projects to accelerate product commercialization.

Sustainability and Growth The company’s focus on expanding operations and building a robust pipeline suggests potential interest in supply chain solutions, raw material sourcing, and manufacturing partnerships to support increased production capacity.